The most recent study, posted in January of 2018, suggest that previous claims about CBD and Parkinson’s to be probable. The endocannabinoid system has shown to play a huge role in neuropathological basis of Parkinson’s Disease. The study focuses specifically on the interactions of CB1 receptors, CB2 receptors and monoacylglycerol lipase (MAGL) gene expression. The study shows that these are closely related to neuropathological process of Parkinson’s Disease. Therefore, realizing the possible benefit of CBD as a potential therapeutic tool for those who are suffering while living with the side effects of Parkinson’s.